Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

Due to the CD1d restricted recognition of altered glycolipids, Vα24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-the shelf-therapeutics across Human Leukocyte Antigen (HLA) bar...

Descripción completa

Detalles Bibliográficos
Autores principales: Poels, Renée, Drent, Esther, Lameris, Roeland, Katsarou, Afroditi, Themeli, Maria, van der Vliet, Hans J., de Gruijl, Tanja D., van de Donk, Niels W. C. J., Mutis, Tuna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865760/
https://www.ncbi.nlm.nih.gov/pubmed/33499253
http://dx.doi.org/10.3390/ijms22031096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865760/
https://www.ncbi.nlm.nih.gov/pubmed/33499253
http://dx.doi.org/10.3390/ijms22031096

Ejemplares similares